Study: More people show interest in weight loss
CHICAGO — The number of working people concerned about their weight is on the rise, according to a new study.
Results of a poll released Tuesday by ComPsych, a company that calls itself the world’s largest provider of employee assistance programs, indicated that 43% of employees cited weight loss as their primary health concern, a number that was 10% higher than in 2011.
"As individuals continue to grapple with weight problems, it’s no shock that weight management is again the top issue this year," ComPsych chairman and CEO Richard Chaifetz said. "With the impact that obesity and weight issues have on corporate healthcare costs, more and more employers are providing comprehensive wellness programs."
An additional 20% cited exercise as their primary health concern; 18% said stress; 10% said diet improvement; 5% said quitting smoking; and 1% cited other issues.
Report: Court OKs agreement between GSK, Apotex over generic Paxil CR
NEW YORK — GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.
According to a Bloomberg Businessweek report, U.S. District Court judge Joe Pisano ruled the agreement was valid.
In 2008, generic drug maker Mylan entered an agreement with GSK to launch a generic version of Paxil CR. In September 2010, Mylan obtained a temporary restraining order against Apotex when the latter launched its generic version of the drug. One month later, a U.S. District Court denied a motion for a preliminary injunction filed by Mylan to prevent Apotex from making a generic version of the antidepressant drug.
“The language plainly states that GSK may commence marketing and selling of authorized generic Paxil CR after Mylan’s two-year period of exclusivity,” Pisano ruled. “GSK did exactly that. It marketed and sold authorized generic Paxil CR to Apotex.”
Report: GSK recalls blood-pressure drug made at Novartis plant
NEW YORK — GlaxoSmithKline has recalled nearly 400,000 bottles of a hypertension drug that were distributed in the United States, according to published reports.
Reuters Health reported that GSK was recalling 394,230 bottles of its DynaCirc CR after the drug’s manufacturer, Novartis, reported inconsistent packaging practices. The generic drug is manufactured at a Novartis plant in Lincoln, Neb.
No adverse events were reported, GSK was quoted as saying, but the drug maker elected to put forth a recall as a precautionary measure.